Britain and America have forged a key commercial pact that will preserve zero levies on UK drug shipments entering the American market.
The Terms of the Deal
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the NHS. This pledge secures that import taxes on these crucial exports will remain at nothing for a timeframe of three years.
This deal is in response to earlier statements to hike duties on patented pharmaceutical imports, with potential rates discussed up to 100%.
"This agreement with the Britain strengthens the international landscape for innovative medicines and introduces long-overdue fairness to U.S.–U.K. drug exports," an announcement noted.
Commercial Significance
Drugs constitute one of the the United Kingdom's most significant goods shipped to the US, which is by far the primary destination for large companies like GSK and AstraZeneca.
Statistics show that in the year leading up to September, the UK shipped drugs valued at over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This guarantee secures work, boosts funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister stated.
Specific UK Commitments
The pact includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. In the past, rebates exceeded 20%.
Broader Context
The deal comes amid a ongoing dispute between the sector and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that US patients were charged several times more for the identical medicines than consumers in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been delayed or cancelled, while major expansions have been announced toward projects in the United States.
One official stated that the NHS needed to spend more on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the previous ten-year period.
